Tonabersat

Drug Profile

Tonabersat

Alternative Names: SB-220453; USL-260

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Proximagen
  • Class Antimigraines; Benzamides; Benzopyrans
  • Mechanism of Action Gap junction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Epilepsy
  • Discontinued Migraine; Neuropathic pain

Most Recent Events

  • 29 Apr 2014 Phase I development of tonabersat in Epilepsy is ongoing
  • 14 Aug 2012 Proximagen has been acquired by Upsher-Smith
  • 14 Apr 2010 Proximagen exclusively sublicenses tonabersat to Upsher-Smith Laboratories for North America ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top